#aging research

1 article

A wide, softly lit editorial still life on a pale warm-gray stone surface, shot from a slightly elevated three-quarter angle. On the left, a small cluster of fresh yellow-gold onions with papery skins, one cut in half to show its pale concentric layers, sits beside a few dusty-red capers and a sprig of dill. These are natural quercetin sources and read as quiet botanical details. In the center, a minimalist glass apothecary dish holds a few small, round, off-white tablets. Beside it, a slim amber glass vial lies on its side with a plain unlabeled cap.

On the right, a neatly arranged clinical element: a vintage-style wooden-handled stopwatch and a crisp paper stride-length measuring tape curled in a loose spiral, hinting at the 6-minute walk test and gait speed measures. Behind these, a softly out-of-focus wall of pale sage green with a subtle shadow of a window frame cast diagonally across it. A single translucent anatomical line drawing of lungs, rendered in fine charcoal ink on cream paper, leans against the wall, its delicate branching bronchi echoing the veining of a nearby green leaf.

Lighting is soft morning daylight from the upper left, creating gentle long shadows and a calm, thoughtful mood. The palette is muted and modern: butter yellow, sage, cream, warm gray, with small accents of terracotta and amber. Shallow depth of field keeps the tablets and onion sharp while the background melts into a creamy blur. Generous negative space across the upper right makes room for headline overlay. The composition feels like a contemporary science journal or wellness-research magazine cover: clean, tactile, restrained, with subtle film grain and natural color grading. No text, no logos, no people, no futuristic elements.

다사티닙·퀘르세틴을 처음 투여받은 인간: 14명 IPF 파일럿이 보여준 것과 보여주지 못한 것

BY DR. SYNAPSE · 2026년 10월 15일

2019년 연구팀은 치명적인 폐 질환을 앓고 있던 14명의 환자에게 세놀리틱 조합인 다사티닙과 퀘르세틴을 최초로 투여했습니다. 3주간 간헐적으로 복용한 뒤, 참가자들은 6분 보행 거리·보행 속도·의자 일어서기 시간에서 의미 있는 개선을 보였지만 폐 기능 자체는 변하지 않았습니다. 파일럿 연구에서는 중대한 부작용 1건과 호흡기·피부·위장관 불편감이 빈번히 보고되었습니다. 다만 이 연구는 암 치료제와 고용량 플라보노이드를 결합한 개방형, 대조군 없는 시험이며 보충제 프로토콜이 아니라는 점을 기억해야 합니다.